Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "D3"

68 News Found

Shelter Pharma launches D3 cure capsules
News | December 16, 2025

Shelter Pharma launches D3 cure capsules

This launch is part of the company's strategy to expand its nutraceutical portfolio


BASF launches combined vitamin A and D3 product for animal nutrition
News | October 16, 2025

BASF launches combined vitamin A and D3 product for animal nutrition

Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation


Fermenta's plant-based Vitamin D3 is 'Innovation of the Year'
News | March 07, 2025

Fermenta's plant-based Vitamin D3 is 'Innovation of the Year'

VITADEETM Green is a 100% plant-based Vitamin D3 suitable for food & nutraceuticals


AbbVie signals major oncology momentum at ASCO
R&D | May 25, 2026

AbbVie signals major oncology momentum at ASCO

With standout ADC and t-cell engager response data across hard-to-treat cancers


AstraZeneca to showcase cancer pipeline push at ASCO 2026
R&D | May 25, 2026

AstraZeneca to showcase cancer pipeline push at ASCO 2026

Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies


Maarga Mind Care launches integrative day care program to bridge mental health recovery gap
Healthcare | April 27, 2026

Maarga Mind Care launches integrative day care program to bridge mental health recovery gap

New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery


ModeX doses first patients in trial of next-gen T-cell engager for aggressive B-cell lymphoma
Clinical Trials | April 24, 2026

ModeX doses first patients in trial of next-gen T-cell engager for aggressive B-cell lymphoma

The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack


Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial
Clinical Trials | April 14, 2026

Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial

BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study